Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection.
antiviral therapy
cirrhosis
insulin resistance
lipid metabolism
viral hepatitis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
01 Jul 2019
01 Jul 2019
Historique:
received:
16
04
2019
accepted:
02
07
2019
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
1
8
2019
Statut:
ppublish
Résumé
We conducted a pilot study assessing the feasibility, efficacy, and safety of a simplified combination HIV antiretroviral and hepatitis C virus (HCV) antiviral regimen in HIV-HCV coinfection. Participants on suppressive antiretrovirals and HCV genotype 1 infection were switched to single-tablet daily-dosed elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) and 1 month later initiated single-tablet-regimen daily-dosed ledipasvir-sofosbuvir for 12 weeks. E/C/F/TAF was continued during HCV treatment and for 12 weeks after. Twenty-six individuals were screened, 25 enrolled, and 23 completed all HIV and HCV treatment. Participants were predominantly male, with a mean age (SD) of 55 (7.5) years. The median transient elastography score (interquartile range [IQR]) was 5.9 (5.3 to 7.6) kPa, and the mean CD4 count (SD) was 579 (223) cells/µL. The median adherence to HCV medications, assessed by pill count, was 100% (95% confidence interval [CI], 100%-100%), and HIV ranged from 99% to 100% (100%; 95% CI, 90%-100%) over the 7-month study duration. HIV undetectability was maintained in all but 1 participant enrolled with unsuspected multiclass resistance. Treatment was well tolerated, with no study medication modification due to adverse events and no serious adverse event related to the study drug. All participants achieved sustained virological response. The mean CD4 count (SD) increased to 673 (361) cells/µL, and the fibrosis score (IQR) declined to 5.2 (4.4 to 7.4) kPa by week 12 after HCV treatment. There was no treatment effect on glucose metabolism. Cholesterol increased during and after treatment. Provision of this 2-tablet daily HIV-HCV regimen is feasible, well tolerated, and safe, avoids drug-drug interactions between HIV and HCV medications, maintains HIV suppression in the absence of drug resistance, and is highly curative of HCV.
Sections du résumé
BACKGROUND
BACKGROUND
We conducted a pilot study assessing the feasibility, efficacy, and safety of a simplified combination HIV antiretroviral and hepatitis C virus (HCV) antiviral regimen in HIV-HCV coinfection.
METHODS
METHODS
Participants on suppressive antiretrovirals and HCV genotype 1 infection were switched to single-tablet daily-dosed elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) and 1 month later initiated single-tablet-regimen daily-dosed ledipasvir-sofosbuvir for 12 weeks. E/C/F/TAF was continued during HCV treatment and for 12 weeks after.
RESULTS
RESULTS
Twenty-six individuals were screened, 25 enrolled, and 23 completed all HIV and HCV treatment. Participants were predominantly male, with a mean age (SD) of 55 (7.5) years. The median transient elastography score (interquartile range [IQR]) was 5.9 (5.3 to 7.6) kPa, and the mean CD4 count (SD) was 579 (223) cells/µL. The median adherence to HCV medications, assessed by pill count, was 100% (95% confidence interval [CI], 100%-100%), and HIV ranged from 99% to 100% (100%; 95% CI, 90%-100%) over the 7-month study duration. HIV undetectability was maintained in all but 1 participant enrolled with unsuspected multiclass resistance. Treatment was well tolerated, with no study medication modification due to adverse events and no serious adverse event related to the study drug. All participants achieved sustained virological response. The mean CD4 count (SD) increased to 673 (361) cells/µL, and the fibrosis score (IQR) declined to 5.2 (4.4 to 7.4) kPa by week 12 after HCV treatment. There was no treatment effect on glucose metabolism. Cholesterol increased during and after treatment.
CONCLUSIONS
CONCLUSIONS
Provision of this 2-tablet daily HIV-HCV regimen is feasible, well tolerated, and safe, avoids drug-drug interactions between HIV and HCV medications, maintains HIV suppression in the absence of drug resistance, and is highly curative of HCV.
Identifiants
pubmed: 31363776
pii: 5528099
doi: 10.1093/ofid/ofz318
pmc: PMC6667714
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Hepatology. 1999 Oct;30(4):1054-8
pubmed: 10498659
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71
pubmed: 10535997
N Engl J Med. 2001 Jul 5;345(1):41-52
pubmed: 11439948
Transplantation. 2001 Sep 27;72(6):1066-72
pubmed: 11579302
JAMA. 2003 Jun 11;289(22):2978-82
pubmed: 12799406
Am J Gastroenterol. 2003 May;98(5):1150-4
pubmed: 12809841
Lancet. 2003 Nov 22;362(9397):1708-13
pubmed: 14643119
Arch Intern Med. 2005 May 23;165(10):1179-84
pubmed: 15911733
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S105-9
pubmed: 16265607
J Viral Hepat. 2006 Jan;13(1):56-61
pubmed: 16364083
Am J Gastroenterol. 2006 Dec;101(12):2752-9
pubmed: 17026566
Diabetes Care. 2006 Nov;29(11):2462-6
pubmed: 17065685
J Hepatol. 2008 Jul;49(1):9-16
pubmed: 18486265
Hepatol Res. 2009 Feb;39(2):195-9
pubmed: 19054155
J Hepatol. 2009 Dec;51(6):984-90
pubmed: 19695729
Hepatology. 2009 Oct;50(4):1030-7
pubmed: 19787818
World J Gastroenterol. 2010 May 14;16(18):2265-71
pubmed: 20458764
Diabetes Care. 2012 May;35(5):1090-4
pubmed: 22399695
Gastroenterology. 2012 May;142(6):1324-1334.e3
pubmed: 22537439
Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5
pubmed: 22715208
AIDS. 2012 Sep 10;26(14):1789-94
pubmed: 22739388
Viruses. 2013 May 23;5(5):1292-324
pubmed: 23698400
J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):587-96
pubmed: 24326606
N Engl J Med. 2014 Apr 24;370(17):1594-603
pubmed: 24720703
N Engl J Med. 2014 May 15;370(20):1889-98
pubmed: 24725239
Clin Mol Hepatol. 2014 Mar;20(1):38-46
pubmed: 24757657
Lancet. 2015 Jun 27;385(9987):2606-15
pubmed: 25890673
N Engl J Med. 2015 Dec 31;373(27):2599-607
pubmed: 26571066
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Pharmacotherapy. 2016 Apr;36(4):385-401
pubmed: 26923931
Lancet HIV. 2016 Dec;3(12):e561-e568
pubmed: 27765666
HIV Med. 2017 Aug;18(7):445-451
pubmed: 27882706
Pharmacol Res Perspect. 2017 Oct;5(5):
pubmed: 28971607
Am Heart J. 2018 Apr;198:4-17
pubmed: 29653647
J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119
pubmed: 29746648
J Viral Hepat. 2018 Dec;25(12):1507-1514
pubmed: 30141236
Open Forum Infect Dis. 2018 Jul 30;5(8):ofy189
pubmed: 30151414
Gastroenterology. 2019 Mar;156(4):987-996.e8
pubmed: 30445009
CMAJ Open. 2019 Jan 8;7(1):E1-E7
pubmed: 30622108
AIDS. 1998 Oct 22;12(15):F167-73
pubmed: 9814858